doxorubicin hydrochloride / Generic mfg. - LARVOL DELTA

Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study. (PubMed, Lancet Haematol) - P2 | "In patients with mostly CD30-expressing peripheral T-cell lymphomas other than non-anaplastic large-cell lymphoma, CHEP-BV (with or without autologous HSCT) followed by brentuximab vedotin consolidation was safe and active."

Journal • P2 data • Bone Marrow Transplantation • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Novel Coronavirus Disease • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • Transplantation • TNFRSF8

Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. (PubMed, N Engl J Med) - P3 | "N+AVD resulted in longer progression-free survival than BV+AVD in adolescents and adults with stage III or IV advanced-stage classic Hodgkin's lymphoma and had a better side-effect profile. (Funded by the National Cancer Institute of the National Institutes of Health and others; S1826 ClinicalTrials.gov number, NCT03907488.)."

Clinical • Journal • Metastases • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Pediatrics

Low dose pembrolizumab in addition to neoadjuvant anthracycline and taxane in triple-negative breast cancer: A randomized controlled trial (ESMO 2025) - "Patients with untreated stage II-III TNBC without access to standard dose pembrolizumab (SDPm) were randomized (1:1) to receive neoadjuvant dose-dense chemotherapy (4 cycles of doxorubicin and cyclophosphamide followed by 4 cycles of paclitaxel) with or without 50 mg LDPm administered every 6 weeks for 3 cycles. Conclusions The absolute benefit with LDPm appears numerically comparable to that observed with SDPm in the KN522 trial. Therefore, in resource-constrained settings where SDPm is inaccessible, a low-dose alternative strategy may provide a viable treatment option in patients with TNBC."

Clinical • Late-breaking abstract • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Primary Results from the HR+/HER2- Cohort of TBCRC-053 (P-RAD): A Randomized Trial of No, Low, or High Dose Preoperative RADiation with Pembrolizumab and Chemotherapy in Node-Positive, HER2-Negative Breast Cancer (SABCS 2025) - P2 | "Patients subsequently received pembrolizumab with 12 weeks of paclitaxel, followed by 4 cycles of adriamycin-cyclophosphamide (q2wk or q3wk) with pembrolizumab (200 mg q3 wks or 400 mg q6 wks). The addition of 24Gy preop RT to aPD1 significantly increased tumor TCI in HR+/HER2- early-stage BC. Non-irradiated nodal response rates were promising despite over one-third of the study population with grade 1/2 tumors and high disease burden, laying the foundation for a future randomized trial comparing the efficacy of this novel approach against standard of care for node-positive HR+/HER2- BC."

Clinical • IO biomarker • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • CD8 • HER-2 • PGR

Venous Thrombosis in Newly Diagnosed Multiple Myeloma: A Multi-Institutional Study from India (IMS 2026) - "The predominance of low-risk scores was largely attributable to universal Asian ethnicity (−3 points), frequent use of aspirin thromboprophylaxis (69%; −3 points), low prevalence of obesity (16%), prior VTE (1.2%), and central venous catheter use (1.7%), along with the absence of doxorubicin exposure. In this large multicenter Indian cohort, the incidence of VTE in NDMM was remarkably low. The IMPEDE VTE score showed poor predictive performance, suggesting limited applicability in this population. Most patients were classified as low risk likely reflecting the influence of Asian ethnicity and a low prevalence of major thrombotic risk factors."

Clinical • Cardiovascular • Genetic Disorders • Hematological Malignancies • Multiple Myeloma • Obesity • Thrombosis • Venous Thromboembolism

Repurposing Polyether Ionophores to Target Stem-Like Compartments and Microenvironmental Resistance in Multiple Myeloma (IMS 2026) - "We hypothesized that the polyether ionophores salinomycin (SAL) and monensin (MON), known to kill cancer stem-like cells in solid tumors, would target the Hoechst-low side-population (SP) compartment of MM...Both compounds synergized (Chou-Talalay CI< 0.9) with bortezomib, carfilzomib, lenalidomide, pomalidomide, doxorubicin, dexamethasone and melphalan, and significantly reduced subcutaneous RPMI-S xenograft growth in NSG mice without overt toxicity. SAL and MON are mechanistically convergent, stroma-resistant and cancer stem-like cell-directed agents that dismantle the bioenergetic, translational and survival machinery of the MM SP compartment, synergize with standard MM therapies and show in vivo efficacy without overt toxicity, supporting their further development for MM combination strategies. This study was supported by the NextGenerationEU project No.09I03-03-V04-00451 (JJ)."

Hematological Malignancies • Multiple Myeloma • Solid Tumor • ANXA5 • BBC3 • CCNB1 • CDKN1A • CHAC1 • CHEK1 • DDIT3 • EIF4EBP1 • GDF15 • IRF4 • MAP1LC3B • MYC • PMAIP1 • SDC1 • SIRT1 • SQSTM1

Neutrophils Promote Multiple Myeloma Progression via Activation of PAD4 (IMS 2026) - "Targeting cfDNA with Pulmozyme or inhibiting PAD4 abrogated neutrophil-mediated protection and restored sensitivity to doxorubicin and melphalan. Our findings identify activation of neutrophil PAD4 as a result of myeloma-neutrophil interaction driving NET formation and cfDNA release as a novel mechanism of BM microenvironment-mediated myeloma progression and drug resistance. Targeting this pathway through PAD4 inhibition suppresses myeloma growth and restores therapy sensitivity, highlighting a promising therapeutic strategy in multiple myeloma."

Hematological Malignancies • Multiple Myeloma • HMGB1 • SDC1

Multi-Omics Profiling Unveils Exclusive Molecular Signature of Multiple Myeloma Cells Harbouring Differential TP53 Genetic Perturbations (IMS 2026) - "Drug perturbation studies using genotoxic(doxorubicin, melphalan) and non-genotoxic(nutlin-3) agents demonstrated TP53 haploinsufficiency, with a progressive reduction in drug sensitivity from WT/WT to WT/- to -/- cells. Our preliminary findings suggest that TP53 abnormalities in MM involve more than just loss of its TS function. The extent of TP53 copy-number loss is also crucial as it contributed to distinct biological states that may drive MM through different mechanisms.Ongoing work aims to define the functional relevance of pathways uniquely associated with specific TP53 abnormalities in MM."

Hematological Malignancies • Multiple Myeloma • ADAR • IL6R • IRF4 • KRAS • STAT3 • TP53

Neoadjuvant rilvegostomig (R) + trastuzumab deruxtecan (T-DXd) in high-risk HER2-negative breast cancer: Results from the I-SPY 2.2 trial. (ASCO 2026) - P2 | "All HER2-negative subtypes were eligible for R + T-DXd in Block A. Predicted responders at the end of Block A or B could undergo surgery; otherwise, they continued to Block B +/- C. Block B pts received paclitaxel +/- carboplatin +/- pembrolizumab and Block C pts doxorubicin + cyclophosphamide (AC) +/- pembrolizumab, HR+ immune+ received IO in Blocks B/C. When considering the full treatment strategy including block B and C regimens, experimental strategies had similar EpCR rates vs. controls in immune+ subtypes but block A rates exceeded pre-defined goal thresholds. This infers that treatment beginning with R + T-DXd has equivalent efficacy to standard of care for immune+ pts, but 64% pts with pCR skip chemotherapy (Block B) and 97% avoid AC (Block C)."

Clinical • IO biomarker • Late-breaking abstract • Alopecia • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Immunology • Interstitial Lung Disease • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor • HER-2 • PROCR • TIGIT

Final results of a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin, and pazopanib: 2ND-STEP study, JCOG1802. (ASCO 2026) - "Funded by Japan Agency for Medical Research and Development (AMED) Clinical Trial Registration Number: jRCTs031190152 Background: The optimal second-line treatment for advanced soft tissue sarcomas (STS) after doxorubicin therapy remains unclear. This trial aimed to identify the most promising agent among trabectedin, eribulin, and pazopanib for subsequent phase III comparison against gemcitabine plus docetaxel (GD), which has traditionally been considered a standard treatment... Consistent with the primary analysis, pazopanib generally showed favorable PFS, OS, and DCR among the three agents. Based on these results, pazopanib was identified as the most appropriate candidate to be compared with GD in a phase III trial, which is currently being planned."

Clinical • Metastases • P2 data • Leiomyosarcoma • Liposarcoma • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial. (PubMed, Nat Med) - P3 | "We conducted a double-blind, placebo-controlled phase 3 study (KEYNOTE-756) in which patients with previously untreated ER+/HER2- grade 3 high-risk invasive breast cancer (T1c-2 (≥2 cm), cN1-2 or T3-4, cN0-2) were randomly assigned (1:1) to neoadjuvant pembrolizumab 200 mg or placebo Q3W given with paclitaxel QW for 12 weeks, followed by four cycles of doxorubicin or epirubicin plus cyclophosphamide Q2W or Q3W. Follow-up continues for event-free survival. ClinicalTrials.gov identifier: NCT03725059 ."

Journal • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2

Association of Prior Local Therapy with Outcomes Within Systemic Therapy Regimen Cohorts in Advanced Soft Tissue Sarcoma: A Retrospective Cohort Study. (PubMed, Cancers (Basel)) - " This retrospective cohort included 75 patients with recurrent or metastatic STS who contributed 155 treatment episodes: doxorubicin (n = 44), trabectedin (n = 31), pazopanib (n = 42), and eribulin (n = 38). No between-regimen differences were formally tested. These findings support individualized multidisciplinary assessment and external validation."

Journal • Retrospective data • Leiomyosarcoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Prognostic Factors for Overall Survival in the VESPER Trial: Basal Molecular Subtype Is a Relevant Key Factor. (PubMed, Eur Urol Oncol) - P3 | "We identified four factors prognostic for OS for patients with MIBC treated with NAC in VESPER. Basal molecular subtype was the most significant prognostic factor for OS, as it was independent of the treatment arm, and showed high prognostic value, in particular during the first year after randomization."

Biomarker • Journal • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

FEASIBILITY AND CLINICAL EFFICACY OF ATEZOLIZUMAB CONSOLIDATION IN HIGH RISK DIFFUSE LARGE B-CELL LYMPHOMA: FINAL ANALYSIS OF THE HOVON 151 (EHA 2024) - "Background: The 2-year disease-free survival (DFS) rate following rituximab, cyclophosphamide, doxorubicin, vincristine, andprednisolone (R-CHOP) in high-risk diffuse large B-cell lymphoma (DLBCL) patients achieving completemetabolic remission (CMR) is 78%. Atezolizumab consolidation therapy demonstrated a significant improvement in DFS for patients with high riskDLBCL compared to historical benchmarks. The remarkable 2-year OS rate of 96. 3% stands out as one of thehighest observed outcomes for high risk DLBCL, with the majority of patients exhibiting chemo-sensitivedisease at relapse."

Clinical • CNS Disorders • Diffuse Large B Cell Lymphoma • Endocrine Disorders • Follicular Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Indolent Lymphoma • Infectious Disease • Lymphoma • Musculoskeletal Diseases • Non-Hodgkin’s Lymphoma • Novel Coronavirus Disease • Oncology • Rheumatology

DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC) (ESMO 2025) - P3 | "We report neoadjuvant T-DXd or T-DXd-THP vs dose-dense doxorubicin + cyclophosphamide (ddAC)-THP in a phase 3, multicenter, open-label, randomized study. Table: 291O T-DXd-THP ddAC-THP Full analysis set, n 321 320 pCR rate, %* 67.3 56.3 ΔpCR vs ddAC-THP, % (95% CI; P value) † 11.2 (4.0, 18.3; 0.003) − EFS hazard ratio (95% CI) ‡ 0.56 (0.26, 1.17) − Safety analysis set, n 320 312 Any SAE, n (%) 34 (10.6) 63 (20.2) Any AE leading to, n (%) Dose reduction 58 (18.1) 60 (19.2) Dose interruption 121 (37.8) 170 (54.5) Drug discontinuation 45 (14.1) 31 (9.9) Death 2 (0.6) 2 (0.6) Drug-related adjudicated ILD / pneumonitis, n (%) 14 (4.4) 16 (5.1) Grade ≥3 2 (0.6) 6 (1.9) 5 1 (0.3) 1 (0.3) Left ventricular dysfunction, n (%) 6 (1.9) 28 (9.0) Grade ≥3 1 (0.3) 7 (2.2) *By blinded central review † Stratified Miettinen & Nurminen method; P value crossed the 0.03 prespecified boundary ‡ 4.5% maturity Conclusions Neoadjuvant T-DXd-THP demonstrated a clinically meaningful and..."

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

TRPML1 loss disrupts lysosome-mitochondria homeostasis and sensitizes MDA-MB-231 triple-negative breast cancer cells to chemotherapy. (PubMed, J Biol Chem) - "Importantly, ML1-KD cells showed enhanced responses to otherwise subeffective concentrations of doxorubicin and paclitaxel. Together, our findings support TRPML1-dependent lysosomal signaling as an important contributor to mitochondrial-metabolic resilience and chemotherapy responsiveness in MDA-MB-231 TNBC cells."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CASP3 • CASP7 • TFEB

Doxorubicin-Trabectedin in Leiomyosarcoma. (PubMed, N Engl J Med) - No abstract available

Journal • Leiomyosarcoma • Oncology • Sarcoma • Solid Tumor

Primary results from the triple-negative cohort of TBCRC-053 (P-RAD): A randomized trial of no, low, or high dose preoperative radiation with pembrolizumab and chemotherapy in node-positive breast cancer. (ASCO 2026) - P2 | "Patients subsequently received pembro (200 mg q3w or 400 mg q6w) with 12 wks of paclitaxel/carboplatin, followed by four cycles of doxorubicin-cyclophosphamide (q2w or q3w) with pembro, surgery and adjuvant therapy. The addition of preoperative RT to pembro significantly increased 2-wk TCI and yielded high rates of ypN0 and pCR after chemo-immunotherapy, with the numerically highest ypN0 rate observed in the 9Gy arm. 2-wk TCI correlated strongly with surgical ypN0 status. A larger study that tests whether preoperative RT and pembro increases pCR should be conducted in node-positive TNBC."

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD8 • HER-2

Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial. (PubMed, Lancet Respir Med) - P3 | "Combination therapy with lurbinectedin plus doxorubicin did not improve overall survival versus control in patients with relapsed SCLC. However, lurbinectedin plus doxorubicin showed a favourable haematological safety profile compared with control."

Journal • P3 data • Hematological Disorders • Lung Cancer • Neuroendocrine Tumor • Neutropenia • Oncology • Small Cell Lung Cancer • Solid Tumor • Thrombocytopenia

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study. (PubMed, Br J Haematol) - P1 | "Glofitamab was investigated with obinutuzumab/rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (G/R-CHOP) in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) who had ≥1 prior obinutuzumab/rituximab-containing therapy (NCT03467373). Median progression-free survival was not reached after 44.2 months follow-up. Glofitamab plus G/R-CHOP showed promising benefit in relapsed/refractory B-NHL, supporting future investigation of glofitamab (2.5/10/30 mg) with R-CHOP in untreated diffuse large B-cell lymphoma."

Journal • P1 data • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Fatigue • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Variant Histology in Pediatric NLPBL: Adverse Biology Mitigated by R-CHOP, Including Feasible Early-Stage De-Escalation (SOHO 2026) - "Variant histology identifies a biologically and clinically higher-risk subgroup of pediatric NLPBL. However, this adverse impact appears to be mitigated by R-CHOP, with excellent outcomes—even in patients with variant histology. Our findings further suggest that risk-adapted de-escalation may be feasible in early-stage disease, including observation after complete resection and reduced-cycle R-CHOP for unresected stage 1–2 disease, without an apparent loss of efficacy."

Clinical • B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Nodular Lymphocyte Predominant Hodgkin Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial. (ASCO 2024) - P3 | "The standard therapy involved doxorubicin and cyclophosphamide (AC) followed by taxane treatment. The addition of carboplatin to standard anthracycline followed by taxane therapy significantly improved EFS in patients with early-stage TNBC. The safety profile was consistent with the known expectations for each regimen."

Clinical • Late-breaking abstract • P3 data • Breast Cancer • Infectious Disease • Oncology • Solid Tumor • Triple Negative Breast Cancer • BRCA

Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall (clinicaltrials.gov) - P3 | N=228 | Not yet recruiting | Sponsor: Ohio State University Comprehensive Cancer Center

New P3 trial • Liposarcoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Undifferentiated Pleomorphic Sarcoma

Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial. (PubMed, J Clin Oncol) - P3 | "In the VESPER trial, dd-MVAC improved 3-years PFS over GC. In the neoadjuvant group, a better bladder tumor local control and a significant improvement in 3-year PFS were observed in the dd-MVAC arm."

Journal • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

A RANDOMIZED PHASE III TRIAL OF DOXORUBICIN + PEMBROLIZUMAB VERSUS DOXORUBICIN ALONE FOR TREATMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA AND RELATED POORLY DIFFERENTIATED SARCOMAS: ECOG-ACRIN EA7222 (CTOS 2024) - No abstract available

Clinical • Late-breaking abstract • P3 data • Oncology • Sarcoma • Solid Tumor • Undifferentiated Pleomorphic Sarcoma